Vericel Corp.

How big is Vericel Corp.?

As of Jun 18, Vericel Corp. has a market capitalization of $2.09 billion, with net sales of $238.55 million and a net profit of $2.98 million over the latest four quarters. Shareholder's funds are $291.97 million, and total assets amount to $432.72 million.

As of Jun 18, Vericel Corp. has a market capitalization of 2,089.23 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 238.55 million, while the sum of Net Profit for the same period is 2.98 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 291.97 million and Total Assets at 432.72 million.

What does Vericel Corp. do?

Vericel Corporation is a biopharmaceutical company focused on developing therapies for tissue and organ repair. As of March 2025, it reported net sales of $53 million and a net loss of $11 million, with a market cap of approximately $2.09 billion.

Overview:<BR>Vericel Corporation is an integrated, commercial-stage biopharmaceutical company dedicated to the identification, development, and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs, operating in the Pharmaceuticals & Biotechnology industry with a small-cap market classification.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 53 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,089.23 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 732.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.36 <BR>Return on Equity: 1.01% <BR>Price to Book: 7.07 <BR><BR>Contact Details:<BR>Address: 64 Sidney St, CAMBRIDGE MA : 02139-4170 <BR>Tel: 1 734 9305555 <BR>Website: https://vcel.com/

Should I buy, sell or hold Vericel Corp.?

Who are in the management team of Vericel Corp.?

As of March 2022, the management team of Vericel Corp. includes Dr. Robert Zerbe (Independent Chairman), Mr. Dominick Colangelo (CEO), and several independent directors: Dr. Steven Gilman, Ms. Heidi Hagen, Mr. Kevin McLaughlin, Mr. Alan Rubino, and Dr. Paul Wotton. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Vericel Corp. includes the following individuals:<BR><BR>- Dr. Robert Zerbe, Independent Chairman of the Board<BR>- Mr. Dominick Colangelo, President, Chief Executive Officer, Director<BR>- Dr. Steven Gilman, Independent Director<BR>- Ms. Heidi Hagen, Independent Director<BR>- Mr. Kevin McLaughlin, Independent Director<BR>- Mr. Alan Rubino, Independent Director<BR>- Dr. Paul Wotton, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is Vericel Corp. technically bullish or bearish?

As of August 25, 2025, Vericel Corp. is in a bearish trend with weak strength, indicated by bearish signals across multiple time frames, and has underperformed the S&P 500 with a year-to-date return of -42.00%.

As of 25 August 2025, the technical trend for Vericel Corp. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, indicated by bearish signals across multiple time frames: MACD is bearish on both weekly and monthly charts, Bollinger Bands are bearish, and daily moving averages are also bearish. The KST is bearish weekly and mildly bearish monthly, while Dow Theory shows a mildly bearish stance on both time frames. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -42.00% compared to the S&P 500's 12.22%.

Is Vericel Corp. overvalued or undervalued?

As of October 17, 2025, Vericel Corp. is considered overvalued with a P/E ratio of 732 and an EV to EBITDA of 517.61, leading to a valuation grade downgrade from attractive to fair, despite recent short-term stock performance outperforming the S&P 500.

As of 17 October 2025, the valuation grade for Vericel Corp. has moved from attractive to fair, indicating a shift in its perceived value. Based on the current metrics, Vericel appears to be overvalued, particularly highlighted by its P/E ratio of 732, which is significantly higher than the industry average, and an EV to EBITDA of 517.61, suggesting an inflated valuation relative to earnings. Additionally, the PEG ratio stands at 1.35, which, while not excessively high, does not compensate for the other concerning ratios.<BR><BR>In comparison to its peers, Vericel's P/E ratio of 732 starkly contrasts with Harmony Biosciences Holdings, which has a P/E of 11.40, and Amphastar Pharmaceuticals at 11.49, both of which are in a more attractive valuation range. Furthermore, Vericel's recent stock performance shows a 1-week return of 10.89%, significantly outperforming the S&P 500's 1.70% return, but it has underperformed over longer periods, with a year-to-date return of -35.68% compared to the S&P 500's 13.30%. This discrepancy in longer-term performance reinforces the notion that Vericel may be overvalued at its current price.